Canada Faces Surge in Inflammatory Bowel Disease Cases by 2045, Global Study Warns
Canada is on track to face a sharp increase in inflammatory bowel disease (IBD) over the next two decades, according to an international study published last month in Nature Portfolio. Co-led by researchers from the University of Calgary, the study analyzed more than 500 population-based studies across 82 countries, mapping over a century of global IBD trends.
The findings paint a sobering picture: while the rate of new diagnoses in Canada has stabilized at around 30 cases per 100,000 people annually, the total number of people living with IBD is expected to climb rapidly. Canada is now entering a phase the study calls “compounding prevalence” — where aging patients add to the existing caseload even as new diagnoses continue. This means that by the 2030s, over 400,000 Canadians could be living with the chronic illness, according to lead researcher Dr. Gilaad Kaplan.
Kaplan, a professor at the University of Calgary and practicing gastroenterologist, warns that Canada’s health-care system must brace for the long-term challenges posed by an aging IBD population. Patients diagnosed in the 1990s are now approaching their 70s, and many will face complications from both IBD and age-related conditions like heart disease, cancer, and dementia.
The study also charts the global evolution of IBD, showing how it has expanded from a rare condition once mostly confined to Western nations to a global health concern. Historically associated with industrialized countries, IBD is now rising in newly urbanized regions of Asia, Latin America, and the Middle East. The shift is attributed to environmental and lifestyle changes — including diet, sanitation, and altered gut microbiomes — that accompany modernization.
In 2025, about 0.8% of Canada’s population lives with IBD. That number is expected to reach 1% by the 2040s. With no known cure, chronic conditions such as Crohn’s disease and ulcerative colitis continue to burden patients with persistent symptoms like abdominal pain, diarrhea, fatigue, and weight loss.
IBD is distinct from irritable bowel syndrome (IBS), which does not cause inflammation or damage to the digestive tract. However, many people with IBD may also suffer from IBS, according to Health Canada.
Canada already has one of the highest rates of IBD in the world, and while this reflects improvements in diagnosis and treatment, it also highlights a growing strain on health-care resources. As people live longer with the condition, long-term care strategies are becoming essential.
The study’s authors, including co-lead Dr. Siew Ng of the Chinese University of Hong Kong, emphasize the need for a two-pronged strategy in Canada: preventing the disease by addressing environmental causes such as diet, and preparing health systems to provide continuous, equitable care for those already affected.
They argue that identifying where a country stands in the global IBD progression offers a valuable opportunity to plan interventions before cases overwhelm the system. As Canada nears the fourth and final phase of IBD prevalence, researchers urge policymakers to act quickly.
Canada, already seen as a leader in IBD research and care, has the opportunity to guide other nations now witnessing their own rise in cases. With its deep experience, Canada could provide insight into how lifestyle changes drive IBD — and how that knowledge can be used to prevent it.
If trends continue, Canada may enter the next phase of IBD evolution by 2045. Whether that transition is managed effectively will depend on decisions made today.